Published by
@ShahidNShah
@ShahidNShah
From tortuosity to the great saphenous vein (GSV), Varithena goes where thermal can’t and enhances results where thermal can
Disease Prevention Life Sciences Tools Drugs Medication Management
Varithena is FDA-approved for treating varicose veins caused by problems with the great saphenous vein (GSV) and related veins in the legs GSV system both above and below the knee. Unique CPT codes and a 30-day shelf-life make Varithena a valuable and efficient way to treat more patients safely - without compromising on outcomes.
Help people struggling with varicose veins overcome their physical and emotional discomfort and return to the activities they love and fast. The convenient, non-surgical treatment is nearly painless, and your patients can return to normal activities the same day.
Varithena® (polidocanol injectable foam) is indicated for the treatment of incompetent great saphenous veins, accessory saphenous veins and visible varicosities of the great saphenous vein (GSV) system above and below the knee. Varithena® improves the symptoms of superficial venous incompetence and the appearance of visible varicosities.
Connecting innovation decision makers to authoritative information, institutions, people and insights.
Medigy accurately delivers healthcare and technology information, news and insight from around the world.
Medigy surfaces the world's best crowdsourced health tech offerings with social interactions and peer reviews.
© 2024 Netspective Foundation, Inc. All Rights Reserved.
Built on Dec 3, 2024 at 12:56pm